drugset / Trial / NCT05392647
Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.
NaSingle-groupOpen-labelTreatment
Summary
The is a phase 2, single-arm, open-label clinical study assessing the efficacy and safety of hetrombopag to increase platelet count in lower-risk MDS patients with thrombocytopenia.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2024-07-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hetrombopag | Small molecule | 5 mg | Oral |